Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope-Reference-Cited by-同舟云学术

Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope

Published:2008-12-20 Issue:36 Volume:26 Page:5845-5848
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Kelley Robin K.¹,Venook Alan P.¹

Affiliation:

1. University of California at San Francisco, San Francisco, CA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.19.7996

Reference37 articles.

1. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis

2. Jiang W, Lu Z, He Y, et al: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395,1997-399,

3. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.

4. Sorafenib in Advanced Hepatocellular Carcinoma

5. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study;Liver Cancer;2022-11-28

2. Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV;OncoTargets and Therapy;2021-07

3. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment;British Journal of Cancer;2019-06-11

4. Identification of a co‐target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach;The FEBS Journal;2018-09-06

5. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database;Cancer Medicine;2018-05-15